What is AXSM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 8.19B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AXSM?

P/E (TTM) is n/a and 52-week range is $119.20 to $260.19 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AXSM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AXSM?

The company profile lists revenue (TTM) near $771M, net income (TTM) near $-19.04B, EPS (TTM) near $-3.76 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Axsome Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 51.5M shares outstanding, ISIN US05464T1043 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Axsome Therapeutics Inc

$AXSM

Health Care · Pharmaceuticals

IR Run Scenarios

$156.32

-5.83%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 925 full-time employees. The company went IPO on 2015-11-19. The firm focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. The company is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.

Employees

925

Website

www.axsome.com/

IPO

2015-11-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)